Ripple Therapeutics announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, an intracameral implant designed to reduce IOP in patients with open-angle glaucoma or ocular hypertension. The biodegradable, sustained-release implant offers repeat dosing capabilities without the use of polymers or excipients, reducing the risk of inflammatory degradation products.

Under this partnership, which Ripple Therapeutics announced in a press release, AbbVie will lead clinical development and commercialization once Ripple completes preclinical development. According to the release, Ripple will receive an upfront payment of $21.8 million, with potential for up to $290 million in milestones and tiered royalties on future net sales.